HSCT for Congenital Amegakaryocitic thrombopecytopenia (CAMT)

Study type:

Study number:

8417036

Type of Stem Cell Treatment:

Allogeneic

Diseases:

Bone marrow failure

Short title:

CAMT study

Primary objective:

Primary Aim: The aim is to evaluate outcomes of paediatric patients with congenial amegakaryocytic thrombocytopenia.

Key inclusion criteria:

• Age at TX < 18years
• First allogeneic transplant
• Diagnosis: Congenial amegakaryocytic thrombocytopenia
• Year of inclusion: Until 2019 (included

Principal investigator:

Clémence Aldebert

EBMT Study coordinator:

Arnaud Dalissier

Study coordinator email:

arnaud.dalissier@upmc.fr